Lv3
250 积分 2025-01-09 加入
Targeted therapy and drug resistance in triple-negative breast cancer: the EGFR axis
1个月前
已完结
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
1个月前
已完结
Development of Dual-Receptor Lysosome-Targeting Chimeras for Protein Degradation
2个月前
已完结
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2个月前
已完结
The interferon regulatory factors and oncogenesis
4个月前
已完结
Ubiquitination modification: critical regulation of IRF family stability and activity
4个月前
已完结
The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2 mutated, non-amplified metastatic breast cancer
5个月前
已完结
The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2 mutated, non-amplified metastatic breast cancer
5个月前
已完结
Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment
5个月前
已完结
Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact
5个月前
已完结
皖公网安备34019202002308
